OncoVista Innovative Therapies, Inc.
OVIT · OTC
9/30/2015 | 6/30/2015 | 3/31/2015 | 12/31/2014 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | -0.01 | 0.10 | 0.00 |
| FCF Yield | -0.28% | -0.53% | -0.67% | -4.86% |
| EV / EBITDA | -31.82 | -18.96 | -37.29 | -0.95 |
| Quality | ||||
| ROIC | 5.87% | 18.36% | 5.55% | 36.30% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.08 | 0.10 | 0.24 | 0.04 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 75.18% | -62.39% | -5.33% | 21.40% |
| Safety | ||||
| Net Debt / EBITDA | -1.32 | -0.35 | -0.98 | -0.12 |
| Interest Coverage | -36.48 | -143.15 | -58.48 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |